ACLX vs JNJ vs BMY vs CRL vs IQV

For growth investors, IQVIA Holdings Inc.

(IQV) is the stronger pick with 5. 9% revenue growth year-over-year, versus -79. 4% for Arcellx, Inc. (ACLX). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 5x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bristol-Myers Squibb Company (BMY) is the cheapest at 16.

5x versus Johnson & Johnson at 39. 0x. On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 9. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 34x versus Johnson & Johnson's 34. 64x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Arcellx, Inc.

(ACLX) delivered a total return of +584. 9%, compared to -46. 3% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: ACLX returned +584. 9% versus BMY's +8. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arcellx, Inc.

(ACLX) is the lower-risk stock at -0. 34β versus Charles River Laboratories International, Inc. 's 1. 52β — meaning CRL is approximately -549% more volatile than ACLX relative to the S&P 500. On balance sheet safety, Arcellx, Inc. (ACLX) carries a lower debt/equity ratio of 24% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IQVIA Holdings Inc.

(IQV) is pulling ahead at 5. 9% versus -79. 4% for Arcellx, Inc. (ACLX). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, IQV leads at 4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.

8% net margin versus -1027. 3% for Arcellx, Inc. — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMY leads at 26. 3% versus -1135. 6% for ACLX. At the gross margin level — before operating expenses — ACLX leads at 70. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 34x versus Johnson & Johnson's 34. 64x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 9. 0x forward P/E versus 19. 5x for Johnson & Johnson — 10. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IQV: 27. 9% to $225. 63.

In this comparison, BMY (4.

3% yield), JNJ (2. 2% yield) pay a dividend. ACLX, CRL, IQV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Arcellx, Inc.

(ACLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 34), +584. 9% 10Y return). Charles River Laboratories International, Inc. (CRL) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACLX: +584. 9%, CRL: +129. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ACLX is a small-cap quality compounder stock; JNJ is a large-cap quality compounder stock; BMY is a mid-cap deep-value stock; CRL is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock. JNJ, BMY pay a dividend while ACLX, CRL, IQV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.